In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3492-3496

  Craig, W A ^a,b   Andes, D R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE MEDOCARIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; IN VIVO STUDY; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYOSITIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROBACTERIACEAE INFECTIONS; EXTREMITIES; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; LUNG DISEASES; METHICILLIN RESISTANCE; MICE; MICE, INBRED ICR; NEUTROPENIA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 54049138039     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01273-07     Document Type: Article

References (25)

1. AAALAC. 2006, posting date. Guide to the Care and Use of Laboratory Animals. AAALAC, Frederick, MD. http://www.aaalac.org.
2. Andes, D., and W. A. Craig. 2003. Pharmacodynamics of the new des-F(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47:3935-3941.
3. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
4. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
5. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
6. Cars, O. 1997. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn. Microbiol. Infect. Dis. 27:29-33.
7. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3):S233-S237.
8. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
9. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
10. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
11. Deshpande, L., P. R. Rhomberg, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary gram-positive and gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75.
12. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
13. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
14. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broadspectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
15. Issa, N. C., M. S. Rouse, K. E. Piper, W. R. Wilson, J. M. Steckelberg, and R. Patel. 2004. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48:73-75.
16. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
17. Lalonde, R. L. 1992. Pharmacodynamics, p. 4.1-4.33. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied pharmacokinetics, 3rd ed. Applied Therapeutics, Inc., Vancouver, WA.
18. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relationships at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
19. McDonald, P. J., B. L. Wetherall, and H. Pruul. 1981. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev. Infect. Dis. 3:38-44.
20. Meinen, J. B., J. T. McClure, and E. Rosin. 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am. J. Vet. Res. 56:1219-1224.
21. NCCLS. 2000. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7, 7th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
22. Perea, S., G. J. Pennick, A. Modak, A. W. Fothergill, D. A. Sutton, D. J. Sheehan, and M. G. Rinaldi. 2000. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob. Agents Chemother. 44:1209-1213.
23. Pruul, H., and P. J. McDonald. 1996. Uptake of cefepime by phagocytosing polymorphonuclear neutrophils and subsequent intracellular killing. Antimicrob. Agents Chemother. 40:1870-1874.
24. Rouse, M. S., M. M. Hein, P. Anguita-Alonso, J. E. Steckelberg, and R. Patel. 2006. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55:333-336.
25. Zuluaga, A. F., B. E. Salazar, C. A. Rodriguez, A. X. Zapata, M. Agudelo, and O. Vesga. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.